Cargando…

Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma

BACKGROUND: Pancreatic cancer is a malignancy with high mortality due to the difficulties in early detection. We investigated and compared the diagnostic and prognostic performance of several blood biomarkers, including microRNA-25 (miR-25), carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antig...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Yan, Song, Lele, Ou, Lei, Lu, You-Yong, Huang, Xianyong, Zeng, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shiraz University of Medical Sciences 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349153/
https://www.ncbi.nlm.nih.gov/pubmed/37456201
http://dx.doi.org/10.30476/ijms.2022.95583.2705
_version_ 1785073839166717952
author Gong, Yan
Song, Lele
Ou, Lei
Lu, You-Yong
Huang, Xianyong
Zeng, Qiang
author_facet Gong, Yan
Song, Lele
Ou, Lei
Lu, You-Yong
Huang, Xianyong
Zeng, Qiang
author_sort Gong, Yan
collection PubMed
description BACKGROUND: Pancreatic cancer is a malignancy with high mortality due to the difficulties in early detection. We investigated and compared the diagnostic and prognostic performance of several blood biomarkers, including microRNA-25 (miR-25), carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), and carbohydrate antigen 125 (CA125). METHODS: A retrospective study was conducted at the Chinese People’s Liberation Army General Hospital from May 2014 to September 2018. Serum specimens were collected, and miR-25 expression levels were measured using real-time quantitative polymerase chain reaction. Serum CA19-9, CEA, and CA125 levels were measured using enzyme-linked immunosorbent assay (ELISA). Statistical analyses including nonparametric test, receiver operator characteristic (ROC) curves, Kaplan-Meier analysis, and subsequent log-rank test were performed with PRISM 5.0 software. Univariate and multivariate analyses were performed with the R software. P<0.05 was considered statistically significant. RESULTS: A total of 250 individuals were recruited, including 75 with pancreatic ductal adenocarcinoma (PDAC), 75 with benign lesions, and 100 healthy controls. miR-25, CA19-9, CEA, and CA125 exhibited an area under the curve (AUC) of 0.88, 0.91, 0.81, and 0.76 with a sensitivity of 78.7%, 74.7%, 37.3%, and 35.7% and specificity of 91.5%, 97.0%, 98.2%, and 98.3%, respectively. The combination of miR-25 and CA19-9 further increased the sensitivity to 93.3% with a specificity of 88.5%. Stage-dependent sensitivity was observed with CA19-9, CEA, and CA125. miR-25 levels significantly stratified the prognosis by median level (4,989.97 copies/mL). CA19-9, CEA, and CA125 levels significantly stratified the prognosis by median levels. Univariate and subsequent multivariate analyses identified tumor (T) stage, CA19-9, and CA125 as independent risk factors for PDAC prognosis. CONCLUSION: The combination of miR-25 and CA19-9 significantly enhanced the detection sensitivity of PDAC. T stage, CA19-9, and CA125 levels were independent risk factors for PDAC prognosis.
format Online
Article
Text
id pubmed-10349153
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Shiraz University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-103491532023-07-16 Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma Gong, Yan Song, Lele Ou, Lei Lu, You-Yong Huang, Xianyong Zeng, Qiang Iran J Med Sci Original Article BACKGROUND: Pancreatic cancer is a malignancy with high mortality due to the difficulties in early detection. We investigated and compared the diagnostic and prognostic performance of several blood biomarkers, including microRNA-25 (miR-25), carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), and carbohydrate antigen 125 (CA125). METHODS: A retrospective study was conducted at the Chinese People’s Liberation Army General Hospital from May 2014 to September 2018. Serum specimens were collected, and miR-25 expression levels were measured using real-time quantitative polymerase chain reaction. Serum CA19-9, CEA, and CA125 levels were measured using enzyme-linked immunosorbent assay (ELISA). Statistical analyses including nonparametric test, receiver operator characteristic (ROC) curves, Kaplan-Meier analysis, and subsequent log-rank test were performed with PRISM 5.0 software. Univariate and multivariate analyses were performed with the R software. P<0.05 was considered statistically significant. RESULTS: A total of 250 individuals were recruited, including 75 with pancreatic ductal adenocarcinoma (PDAC), 75 with benign lesions, and 100 healthy controls. miR-25, CA19-9, CEA, and CA125 exhibited an area under the curve (AUC) of 0.88, 0.91, 0.81, and 0.76 with a sensitivity of 78.7%, 74.7%, 37.3%, and 35.7% and specificity of 91.5%, 97.0%, 98.2%, and 98.3%, respectively. The combination of miR-25 and CA19-9 further increased the sensitivity to 93.3% with a specificity of 88.5%. Stage-dependent sensitivity was observed with CA19-9, CEA, and CA125. miR-25 levels significantly stratified the prognosis by median level (4,989.97 copies/mL). CA19-9, CEA, and CA125 levels significantly stratified the prognosis by median levels. Univariate and subsequent multivariate analyses identified tumor (T) stage, CA19-9, and CA125 as independent risk factors for PDAC prognosis. CONCLUSION: The combination of miR-25 and CA19-9 significantly enhanced the detection sensitivity of PDAC. T stage, CA19-9, and CA125 levels were independent risk factors for PDAC prognosis. Shiraz University of Medical Sciences 2023-07 /pmc/articles/PMC10349153/ /pubmed/37456201 http://dx.doi.org/10.30476/ijms.2022.95583.2705 Text en Copyright: © Iranian Journal of Medical Sciences https://creativecommons.org/licenses/by-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NoDerivatives 4.0 International License. This license allows reusers to copy and distribute the material in any medium or format in unadapted form only, and only so long as attribution is given to the creator. The license allows for commercial use.
spellingShingle Original Article
Gong, Yan
Song, Lele
Ou, Lei
Lu, You-Yong
Huang, Xianyong
Zeng, Qiang
Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma
title Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma
title_full Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma
title_fullStr Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma
title_full_unstemmed Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma
title_short Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma
title_sort diagnostic and prognostic performance of microrna-25, carbohydrate antigen 19-9, carcinoembryonic antigen, and carbohydrate antigen 125 in pancreatic ductal adenocarcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349153/
https://www.ncbi.nlm.nih.gov/pubmed/37456201
http://dx.doi.org/10.30476/ijms.2022.95583.2705
work_keys_str_mv AT gongyan diagnosticandprognosticperformanceofmicrorna25carbohydrateantigen199carcinoembryonicantigenandcarbohydrateantigen125inpancreaticductaladenocarcinoma
AT songlele diagnosticandprognosticperformanceofmicrorna25carbohydrateantigen199carcinoembryonicantigenandcarbohydrateantigen125inpancreaticductaladenocarcinoma
AT oulei diagnosticandprognosticperformanceofmicrorna25carbohydrateantigen199carcinoembryonicantigenandcarbohydrateantigen125inpancreaticductaladenocarcinoma
AT luyouyong diagnosticandprognosticperformanceofmicrorna25carbohydrateantigen199carcinoembryonicantigenandcarbohydrateantigen125inpancreaticductaladenocarcinoma
AT huangxianyong diagnosticandprognosticperformanceofmicrorna25carbohydrateantigen199carcinoembryonicantigenandcarbohydrateantigen125inpancreaticductaladenocarcinoma
AT zengqiang diagnosticandprognosticperformanceofmicrorna25carbohydrateantigen199carcinoembryonicantigenandcarbohydrateantigen125inpancreaticductaladenocarcinoma